Group 1: Company Announcements - Meinian Health plans to participate in the restructuring of Zhejiang Bangjie Holdings, aiming to become the controlling shareholder post-restructuring [1] - Silver Industry's gold and silver product revenues are low, with gold sales contributing 18.67% and silver 4.54% to total revenue in H1 2025 [2] - Tianneng Wind Power has decided to implement long-term production halts for six wholly-owned subsidiaries to optimize resource allocation and focus on core offshore wind power business [3] Group 2: Price and Supply Risks - Tongling Nonferrous Metals reports significant uncertainty in the prices of cathode copper and other main products, with low self-sufficiency in copper concentrate posing supply stability risks [4] - ST Aowei received a notice of termination of listing due to market capitalization falling below 500 million yuan for 20 consecutive trading days [5][6] Group 3: Performance Forecasts - Foton Motor expects a net profit increase of approximately 1551% to around 1.33 billion yuan in 2025, driven by sales growth across various segments [7] - Beimo High-Tech anticipates a net profit of 190 million to 220 million yuan, reflecting a growth of 1076.16% to 1261.87% [8] - Zhongke Sanhuan forecasts a net profit increase of 566.23% to 899.35%, driven by cost control and market expansion [9] - Wancheng Group expects a net profit of 1.23 billion to 1.4 billion yuan, a growth of 222.38% to 266.94% [10] - Wan Yi Technology anticipates a net profit increase of 191.52% to 330.34%, supported by product optimization and cost reduction measures [11] - Nanmo Biology expects a net profit of 24 million to 34 million yuan, a growth of 269.49% to 423.44% [12] - Bai'ao Saitou forecasts a net profit increase of 384.26% to 443.88%, benefiting from overseas market expansion [13] - Hailanxin anticipates a net profit of 40 million to 60 million yuan, a growth of 387.47% to 631.2% [14] - Panzhihua Coal expects a net profit of 318 million to 380 million yuan, a growth of 205.3% to 264.83% [15] - Huaguang New Materials forecasts a net profit increase of 104.67% to 141.88% [16] - Putian Technology expects a net profit of 1.92 million to 2.88 million yuan, a growth of 71.55% to 157.33% [17] - Guoda Special Materials anticipates a net profit increase of 82.61% [18] - Tongkun Co. expects a net profit of 1.95 billion to 2.15 billion yuan, a growth of 62.24% to 78.88% [19] - Yiming Pharmaceutical forecasts a net profit increase of 61.12% to 122.08% [20] - Guosheng Securities expects a net profit of 210 million to 280 million yuan, a growth of 25.44% to 67.25% [21] - Shengyi Technology anticipates a net profit increase of 87% to 98% [22] Group 4: Loss Forecasts - Saifutian expects a loss of 30 million to 45 million yuan, significantly reducing previous losses [23] - Magang Group forecasts a loss of 190 million to 250 million yuan, a substantial reduction in losses [24] - Shennong Seed Industry anticipates a profit of 90 million to 120 million yuan, reversing previous losses [25] - Jifeng Co. expects a profit of 410 million to 495 million yuan, reversing previous losses [26] - Bingchuan Network forecasts a profit of 436 million to 516 million yuan, reversing previous losses [27] - Zhongyou Technology anticipates a profit of 540 million to 640 million yuan, reversing previous losses [28] - Dongfang Biology expects a loss of 523 million yuan [29] - Wantai Biological anticipates a loss of 330 million to 410 million yuan due to market pressures [30] - Anbotong expects a loss of 114 million to 165 million yuan [31] - Shunxin Agriculture forecasts a loss of 116 million to 188 million yuan due to declining sales [32] - Guozhong Water expects a loss of 130 million to 104 million yuan, with potential delisting risks [33] Group 5: Major Contracts - China Communication Signal expects to win 21 major projects worth approximately 5.26 billion yuan [34]

证券代码：688298 证券简称：东方生物 公告编号：2026-003 浙江东方基因生物制品股份有限公司 2025年年度业绩预亏公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 1、经财务部门初步测算，预计2025年年度实现归属于母公司所有者的净利润将出现亏损，实现归属于 母公司所有者的净利润-5.23亿元。 2、归属于母公司所有者扣除非经常性损益后的净利润-5.58亿元。 （二）每股收益：-2.69元。 三、本期业绩变化的主要原因 （一）主营业务影响：本年度公司主营业务保持稳健的发展，但因各产业技术平台战略发展，整体培育 期间持续投入较大，汇兑损失及利息收入对利润的贡献减少，同时计提资产相关折旧摊销费用，计提部 分资产减值损失等原因，使得2025年度净利润亏损。 （二）非经营性损益的影响：报告期内正常的理财收益。 四、风险提示 （一）本年度业绩预告相关财务数据未经注册会计师审计。 （二）截至本公告披露日，公司尚 ...

本年度公司主营业务保持稳健的发展，但因各产业技术平台战略发展，整体培育期间持续投入较大，汇 兑损失及利息收入对利润的贡献减少，同时计提资产相关折旧摊销费用，计提部分资产减值损失等原 因，使得2025年度净利润亏损。 智通财经APP讯，东方生物(688298.SH)发布2025年年度业绩预亏公告，预计2025年年度实现归属于母 公司所有者的净利润将出现亏损，实现归属于母公司所有者的净利润-5.23亿元。 ...

Core Viewpoint - Dongfang Biological (688298.SH) announced a projected net loss of 523 million yuan for the fiscal year 2025, attributed to significant investments in strategic development across various technology platforms, foreign exchange losses, reduced interest income contributions, and increased asset depreciation and impairment losses [1] Group 1 - The company expects a net profit attributable to shareholders of the parent company to be -523 million yuan for the year 2025 [1] - The main business of the company continues to develop steadily despite the anticipated losses [1] - The losses are primarily due to ongoing substantial investments in the cultivation period of various industry technology platforms [1] Group 2 - Foreign exchange losses and a decrease in contributions from interest income have negatively impacted profits [1] - The company has also incurred increased depreciation and amortization expenses related to assets [1] - There are provisions for impairment losses on certain assets contributing to the overall net loss [1]

Group 1 - Meinian Health plans to participate in the restructuring of Zhejiang Bangjie Holdings, aiming to become the controlling shareholder after the completion of the restructuring [3] - Baiyin Nonferrous Metals reported that the revenue from gold and silver products accounted for a low proportion of total operating income, with gold sales contributing 18.67% and silver sales 4.54% in the first half of 2025 [4] - Tiens Wind Power decided to implement a long-term production suspension for six wholly-owned subsidiaries to optimize resource allocation and focus on core businesses [5] Group 2 - Tongling Nonferrous Metals indicated significant uncertainty in the price fluctuations of its main products, with a low self-sufficiency rate for copper concentrate posing supply stability risks [6] - *ST Aowei received a notice of termination of listing due to its market capitalization falling below 500 million yuan for twenty consecutive trading days [7] - Foton Motor expects a net profit increase of approximately 1551% year-on-year for 2025, driven by sales growth in new energy vehicles and overseas markets [9] Group 3 - Beimo High-tech anticipates a net profit increase of 1076.16% to 1261.87% for 2025, supported by cost control and reduced credit impairment losses [10] - Zhongke Sanhuan forecasts a net profit growth of 566.23% to 899.35% for 2025, attributed to technological innovation and improved operational efficiency [12] - Wancheng Group expects a net profit increase of 222.38% to 266.94% for 2025, driven by growth in its retail business and improved sales margins [13] Group 4 - Huayi Technology anticipates a net profit increase of 191.52% to 330.34% for 2025, benefiting from product optimization and cost reduction measures [14] - Nanmo Biology expects a net profit growth of 269.49% to 423.44% for 2025, supported by increased revenue in the biopharmaceutical sector and improved cost control [15] - Baiao Saitu forecasts a net profit increase of 384.26% to 443.88% for 2025, driven by expansion in overseas markets and recovery in the domestic biopharmaceutical industry [16] Group 5 - Hailanxin expects a net profit increase of 387.47% to 631.2% for 2025, supported by advancements in technology and increased market share in marine observation [17] - Panjiang Co. anticipates a net profit growth of 205.3% to 264.83% for 2025, driven by increased coal production and reduced costs [18] - Huaguang New Materials expects a net profit increase of 104.67% to 141.88% for 2025, with significant growth in the electronic sector [20] Group 6 - Guo Sheng Securities forecasts a net profit increase of 25.44% to 67.25% for 2025, supported by active capital market participation and growth in various business segments [25] - Shengyi Technology expects a net profit growth of 87% to 98% for 2025, driven by increased sales of copper-clad laminates [26] - Sifutian anticipates a net loss of 30 million to 45 million yuan for 2025, although this represents a significant reduction in losses compared to the previous year [27] Group 7 - Maanshan Steel expects a net loss of 1.9 billion to 2.5 billion yuan for 2025, with a substantial reduction in losses compared to the previous year [28] - Shennong Seed Industry forecasts a net profit of 90 million to 120 million yuan for 2025, marking a turnaround from previous losses [30] - Jifeng Co. anticipates a net profit of 410 million to 495 million yuan for 2025, achieving a turnaround from losses [31]

（记者 王瀚黎） 每经头条（nbdtoutiao）——水贝黄金平台"杰我睿"兑付危机调查：40倍杠杆对赌，金价越涨平台越 亏！老板自称"还在深圳"，投资者：兑付方案本金打两折，无法接受 每经AI快讯，东方生物1月29日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利润 将出现亏损，实现归属于母公司所有者的净利润-5.23亿元。本年度公司主营业务保持稳健的发展，但 因各产业技术平台战略发展，整体培育期间持续投入较大，汇兑损失及利息收入对利润的贡献减少，同 时计提资产相关折旧摊销费用，计提部分资产减值损失等原因，使得2025年度净利润亏损。报告期内正 常的理财收益。 ...

（一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 1、经财务部门初步测算，预计 2025 年年度实现归属于母公司所有者的净利 润将出现亏损，实现归属于母公司所有者的净利润-5.23 亿元。 证券代码：688298 证券简称：东方生物 公告编号：2026-003 浙江东方基因生物制品股份有限公司 2025 年年度业绩预亏公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （二）非经营性损益的影响：报告期内正常的理财收益。 四、风险提示 （一）本年度业绩预告相关财务数据未经注册会计师审计。 2、归属于母公司所有者扣除非经常性损益后的净利润-5.58 亿元。 3、本次业绩预告未经注册会计师审计。 二、上年同期业绩情况和财务状况 （一）利润总额：-5.85 亿元。归属于母公司所有者的净利润-5.29 亿元； 归属于母公司所有者的扣除非经常性损益的净利润-5.71 亿元。 （二）每股收益：-2.69 元。 三、本期业绩变化的主要原因 （一）主营业务影响 ...

Core Viewpoint - The company, Dongfang Biological, is expected to report a net loss attributable to shareholders of the parent company amounting to 523 million yuan for the fiscal year 2025, indicating a challenging financial outlook [1] Financial Performance Summary - The projected net profit attributable to shareholders of the parent company for 2025 is -523 million yuan, with a net profit excluding non-recurring gains and losses of -558 million yuan [1] - In the same period last year, the total profit was -585 million yuan, with a net profit attributable to shareholders of the parent company at -529 million yuan, and a net profit excluding non-recurring gains and losses of -571 million yuan [1] - The earnings per share for the previous year was reported at -2.69 yuan [1]

东方生物公告称，经初步测算，2025年1月1日至12月31日，公司预计实现归属于母公司所有者的净利 润-5.23亿元，扣除非经常性损益后的净利润-5.58亿元。上年同期归属于母公司所有者的净利润为-5.29 亿元。本期业绩亏损主要因各产业技术平台战略发展培育期投入大，汇兑损失及利息收入对利润贡献减 少，同时计提资产折旧摊销和减值损失。具体财务数据以2025年年度报告为准。 ...

南财智讯1月29日电，东方生物发布业绩预亏公告，预计2025年年度实现归属于上市公司股东的净利润 为-5.23亿元；归属于上市公司股东的扣除非经常性损益后的净利润为-5.58亿元。本期业绩变化的主要 原因：（一）主营业务影响：本年度公司主营业务保持稳健的发展，但因各产业技术平台战略发展，整 体培育期间持续投入较大，汇兑损失及利息收入对利润的贡献减少，同时计提资产相关折旧摊销费用， 计提部分资产减值损失等原因，使得2025年度净利润亏损。（二）非经营性损益的影响：报告期内正常 的理财收益。 ...